Dabrafenib, sold under the brand name Tafinlar among others, is an anti-cancer medication used for the treatment of cancers associated with a mutated version of the gene BRAF.[2] Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth.
The most common side effects include papilloma (warts), headache, nausea, vomiting, hyperkeratosis (thickening and toughening of the skin), hair loss, rash, joint pain, fever and tiredness.[3] When taken in combination with trametinib, the most common side effects include fever, tiredness, nausea, chills, headache, diarrhea, vomiting, joint pain and rash.[3]
Dabrafenib was approved for medical use in the United States in May 2013,[7] and in the European Union in August 2013.[3]
^"Product monograph brand safety updates". Health Canada. February 2024. Retrieved March 24, 2024.
^ ab"Tafinlar- dabrafenib capsule". DailyMed. U.S. National Library of Medicine. June 22, 2022. Archived from the original on January 27, 2023. Retrieved January 27, 2023.
^ abcdCite error: The named reference Tafinlar EPAR was invoked but never defined (see the help page).
^Cite error: The named reference Finlee EPAR was invoked but never defined (see the help page).
^"Tafinlar Product information". Union Register of medicinal products. August 29, 2013. Archived from the original on January 11, 2023. Retrieved December 11, 2023.
^"Finlee Product information". Union Register of medicinal products. November 16, 2023. Archived from the original on November 26, 2023. Retrieved December 11, 2023.
^Cite error: The named reference Tafinlar FDA approval package was invoked but never defined (see the help page).
Dabrafenib, sold under the brand name Tafinlar among others, is an anti-cancer medication used for the treatment of cancers associated with a mutated version...
with the BRAF inhibitor dabrafenib. As a result of this research, on 8 January 2014, the FDA approved the combination of dabrafenib and trametinib for the...
study reported that combining Dabrafenib with a MEK inhibitor trametinib led to even better outcomes. Compared to Dabrafenib alone, progression-free survival...
Hyperkeratosis can also be caused by B-Raf inhibitor drugs such as Vemurafenib and Dabrafenib. It can be treated with urea-containing creams, which dissolve the intercellular...
pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor trametinib. Important prognosis factors for nodular...
Drug Trade name Rac Reference Dabrafenib Tafinlar 0.73 Rosuvastatin Crestor 1.37 in hemodialysis patients Lisinopril Prinivil and others 1.38 Ivacaftor...
pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor trametinib. When arising in the nailbed of a digit...
LHRH, Phase II results for ovarian cancer. Braf inhibitors (vemurafenib, dabrafenib, LGX818) used to treat metastatic melanoma that harbors BRAF V600E mutation...
keratoacanthoma, such as the BRAF inhibitor medications vemurafenib and dabrafenib. Keratoacanthomas presents as a fleshy, elevated and nodular lesion with...
Cancers with hyperactive BRAF (around 2% of NSCLC) can be treated by dabrafenib combined with the MEK inhibitor trametinib; those with activated ROS1...
BRAF-mutated melanoma. Also studied in combination with BRAF inhibitor dabrafenib to treat BRAF-mutated melanoma. PD-325901, for breast cancer, colon cancer...
pembrolizumab, nivolumab, cemiplimab; BRAF inhibitors, such as vemurafenib and dabrafenib; and a MEK inhibitor trametinib. In February 2024, the Food and Drug Administration...
January 2015, trial results compared vemurafenib with the combination of dabrafenib and trametinib for metastatic melanoma. Vemurafenib was approved in the...
anaplastic thyroid cancer harboring such mutations. The combination of dabrafenib and trametinib has shown significant increases in overall survival and...
basal activity and hence is oncogenic. Vemurafenib, encorafenib, and dabrafenib are approved by the FDA for treatment of metastatic melanomas that express...
pembrolizumab, and nivolumab; BRAF inhibitors, such as vemurafenib and dabrafenib; and an MEK inhibitor trametinib. Melanoma List of cutaneous conditions...
V600 are effectively druggable with small molecule inhibitors such as dabrafenib. Unfortunately, drug resistance is observed within 4-6 months after treatment...
2021. Acquired resistance to BRAF inhibitors, such as vemurafenib and dabrafenib, commonly occurs after several months of progression-free tumor response...
Center for Drug Evaluation and Research (2023-03-31). "FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF...
Global Information
